Clinical and Experimental Reproductive Medicine

  • 제32권2호
  • /
  • Pages.155-164
  • /
  • 2005
  • /
  • 2233-8233(pISSN)
  • /
  • 2233-8241(eISSN)
대한생식의학회 (The Korean Society for Reproductive Medicine)
권호 표지

다낭성난소증후군 환자에서 Pioglitazone이 인슐린 민감도, 난소 기능, 난소 기질 내 혈류에 미치는 영향

Effects of Pioglitazone on Insulin Sensitivity, Ovarian Function and Intraovarian Stromal Blood Flow in Women with Polycystic Ovary Syndrome

  • 이향아 (울산대학교 의과대학 서울아산병원 산부인과학교실) ;
  • 김정훈 (울산대학교 의과대학 서울아산병원 산부인과학교실) ;
  • 최정원 (울산대학교 의과대학 서울아산병원 산부인과학교실) ;
  • 박선정 (울산대학교 의과대학 서울아산병원 산부인과학교실) ;
  • 이수정 (울산대학교 의과대학 서울아산병원 산부인과학교실) ;
  • 최은선 (울산대학교 의과대학 서울아산병원 산부인과학교실) ;
  • 김성훈 (울산대학교 의과대학 서울아산병원 산부인과학교실) ;
  • 채희동 (울산대학교 의과대학 서울아산병원 산부인과학교실) ;
  • 손영수 (제주대학교 의과대학 산부인과) ;
  • 강병문 (울산대학교 의과대학 서울아산병원 산부인과학교실)
  • Lee, Hyang-Ah (Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center) ;
  • Kim, Chung-Hoon (Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center) ;
  • Choi, Jeong-Won (Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center) ;
  • Park, Sun-Jung (Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center) ;
  • Lee, Soo-Jeong (Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center) ;
  • Choi, Eun-Sun (Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center) ;
  • Kim, Sung-Hoon (Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center) ;
  • Chae, Hee-Dong (Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center) ;
  • Son, Young-Soo (Department of Obstetrics and Gynecology, College of Medicine, Cheju University) ;
  • Kang, Byung-Moon (Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center)
  • 발행 : 2005.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: This study was performed to investigate the effects of pioglitazone, an insulin sensitizing agent, on insulin resistance, ovarian function and intraovarian stromal blood flow in patients with polycystic ovarian syndrome (PCOS). Material and Methods: Thirty patients with PCOS, aged 18~34 years, were recruited. Criteria for diagnosis of PCOS were as defined in 2003 Rotterdam consensus. They were treated for 6 months with pioglitazone at a dose of 30 mg/day orally. The hormonal blood profile, fasting serum glucose levels, a glycemic response to 75 g oral glucose tolerance test (OGTT), and an ovarian stromal artery (OSA) blood flow were assessed at baseline and after 6 months of treatment. Results: Eighteen (60.0%) of 30 patients treated with pioglitazone demonstrated a spontaneous ovulation After pioglitazone treatment, fasting insulin concentrations, serum glucose levels after 75 g OGTT significantly decreased (p=0.001, p=0.04, respectively), and fasting glucose to insulin (G/I) ratio significantly increased (p<0.001). The pioglitazone treatment induced a significant reduction in serum LH, testosterone (T) and free T levels (p<0.001, p=0.02, p=0.002, respectively). The resistance index (RI) values of OSA significantly increased after treatment (p<0.001). In analyzing pioglitazone-treated patients according to their body mass index (BMI), nonobese group as well as obese group showed a significant improvement in fasting G/I ratio (p<0.01). The pioglitazone treatment induced a significant reduction in serum LH and free T levels in nonobese group (p<0.001, p<0.05, respectively) as well as obese group (p=0.001, p<0.05, respectively). The RI values of OSA significantly increased in both nonobese and obese groups after pioglitazone treatment (p<0.001, p=0.003, respectively). Conclusions: Pioglitazone could ameliorate the glycoinsulinemic metabolism, and this beneficial effects of this drug could improve the endocrine-reproductive condition associated with the decrease of ovarian stromal artery blood flow, in both nonobese and obese patients with PCOS.

키워드

참고문헌

  1. The Rotterdam ESHRE/ASRM-Sponsored PeOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PeOS). Hum Reprod 2004; 19: 41-7 https://doi.org/10.1093/humrep/deh098
  2. Annos T, Taymor ML. Ovarian pathology associated with insulin resistance and acanthosis nigricans. Obstet Gynecol 1981; 58: 662-4
  3. Ciampelli M, Lanzone A. Insulin and polycystic ovary syndrome: a new look at an old subject. Gynecol Endocrinol 1998; 12: 277-92 https://doi.org/10.3109/09513599809015601
  4. Unger JW, Livingston IN, Moss AM. Insulin receptors in the central nervous system: localization, signalling mechanisms and functional aspects. Prog Neurobiol 1991; 36: 343-62 https://doi.org/10.1016/0301-0082(91)90015-S
  5. Salehi M, Bravo-Vera R, Sheikh A. Gouller A, Poretsky L. Pathogenesis of polycystic ovary syndrome: what is the role of obesity? Metabolism 2004; 53: 358-76 https://doi.org/10.1016/j.metabol.2003.10.005
  6. De Leo V, la Marca A,Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 2003; 24: 633-67 https://doi.org/10.1210/er.2002-0015
  7. Hanefeld M. Pharmacokinetics and clinical efficacy of pioglitazone. Int J Clin Pract Suppl 2001; 121: 19 -25
  8. Moghetti P, Castello R, Perrone F, Caputo M, Zanolin E, Muggeo M. Metforrnin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000; 86: 139 -46
  9. Iida KT, Kawakami Y, Suzuki M, Shimano, H, Toyoshima, H, Sone, H, et al. Effect of thiazolidinediones and metforrnin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats. Am J Physiol Endocrinol Metab 2003; 284: 1125 -30
  10. Ishibashi M, Egashira K, Hiasa K, Inoue S, Ni W, Zhao Q, et al. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 2002; 40: 687-93 https://doi.org/10.1161/01.HYP.0000036396.64769.C2
  11. Brettenthaler N, De Geyter C, Huber PR, Keller U. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89: 3835-40 https://doi.org/10.1210/jc.2003-031737
  12. Murakawa H, Hasegawa I, Kurabayashi T, Tanaka K. Polycystic ovary syndrome. Insulin resistance and ovulatory responses to clomiphene citrate. J Reprod Med 1999; 44: 23-7
  13. Glueck CJ, Moreira A, Goldenberg N, Sieve L, Wang P. Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod 2003; 18: 1618-25 https://doi.org/10.1093/humrep/deg343
  14. Mehta RV, Patel KS, Coffler MS, Dahan, MH, Yoo RY, Archer JS, et al. Luteinizing Hormone Secretion is Not Influenced by Insulin Infusion in Women with Polycystic Ovary Syndrome Despite Improved Insulin Sensitivity During Pioglitazone Treatment. J Clin Endocrinol Metab 2005 (in press)
  15. Kirchengast S, Huber 1. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 2001; 16: 1255-60 https://doi.org/10.1093/humrep/16.6.1255
  16. Silfen ME, Denburg MR, Manibo AM, Lobo RA, Jaffe, R, Ferin M, et al. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. J Clin Endocrinol Metab 2003; 88: 4682-8 https://doi.org/10.1210/jc.2003-030617
  17. Battaglia C, Artini PG, D'Ambrogio G, Genazzani AD, Genazzani AR. The role of color Doppler imaging in the diagnosis of polycystic ovary syndrome. Am J Obstet Gynecol 1995; 172: 108-13 https://doi.org/10.1016/0002-9378(95)90094-2
  18. Vrtacnik-Bokal E, Meden-Vrtovec H. Utero-ovarian arterial blood flow and hormonal profile in patients with polycystic ovary syndrome. Hum Reprod 1998; 13: 815-21 https://doi.org/10.1093/humrep/13.4.815
  19. Loverro G, Vicino M, Lorusso F, Vimercati A, Greco P, Selvaggi L. Polycystic ovary syndrome: relationship between insulin sensitivity, sex hormone levels and ovarian stromal blood flow. Gynecol Endocrinol 2001; 15: 142-9 https://doi.org/10.1080/713602806
  20. Battaglia C. The role of ultrasound and Doppler analysis in the diagnosis of polycystic ovary syndrome. Ultrasound Obstet Gynecol 2003; 22: 225 -32 https://doi.org/10.1002/uog.228
  21. Iuomo MJ, Nestler IE. Insulin-lowering drugs in polycystic ovary syndrome. Obstet Gynecol Clin NorthAm 2001; 28: 153-64 https://doi.org/10.1016/S0889-8545(05)70191-1
  22. Ortega-Gonzalez C, Luna S, Hernandez L, Crespo, G, Aguayo, P, Arteaga-Troncoso G, et al. Responses of Serum Androgen and Insulin Resistance to Metformin and Pioglitazone in Obese, Insulin-resistant Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2005
  23. Wallace TM, Matthews DR. The assessment of insulin resistance in man. Diabet Med 2002; 19: 527 -34 https://doi.org/10.1046/j.1464-5491.2002.00745.x
  24. Carmina E, Lobo RA. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2004; 82: 661-5 https://doi.org/10.1016/j.fertnstert.2004.01.041